Boehringer Ingelheim announced the acquisition of privately-held T3 Pharmaceuticals AG (“T3 Pharma”), a clinical stage Swiss biotech company, for an amount of up to 450 million CHF. T3 Pharma has developed a proprietary therapy platform that uses live bacteria to deliver immune-modulating proteins to cancer cells and tumor micro-environments, a statement said. Despite the significant…
Cognizant announced its collaboration with Boehringer Ingelheim, a leading research-driven biopharmaceutical company, to accelerate the speed and quality of drug development. medicinal therapies. Leveraging Veeva Development Cloud, Cognizant will help Boehringer Ingelheim unify medicinal development processes and data into a connected technology ecosystem, improving collaboration between clinical, regulatory and quality functions, the statement said. “Achieving…
Boehringer Ingelheim announced that the Shareholders have appointed Paola Casarosa and Shashank Deshpande to the Board of Managing Directors. They will succeed Michel Pairet, responsible for the Innovation Unit, and Jean Scheftsik de Szolnok, responsible for the Animal Health Business Unit, who informed the Shareholders of their wish to retire at the end of next…
Boehringer Ingelheim announced the signing of an option to acquire Trutino Biosciences Inc., a San Diego-based biotech company. Trutino Biosciences is a pre-clinical stage biotech company dedicated to the discovery and development of next-generation cytokine therapies to treat immuno-oncology and autoimmune diseases. Boehringer Ingelheim is dedicated to a two-pronged research strategy to fight cancers:…
Boehringer Ingelheim India has appointed Vani Manja as Managing Director and Head of Human Pharma, effective January 1, 2021. Vani succeeds Sharad Tyagi, who retired from Boehringer Ingelheim India on December 31, 2020, the company said. In the role, Vani will assume responsibility for the company’s businesses in India, Bangladesh, Nepal and Sri Lanka. She…
Cipla Limited and Boehringer Ingelheim India Pvt. Ltd. (BI) announced that they have entered into a partnership to co-market three new oral anti-diabetics drugs Oboravo (Empagliflozin), Oboravo Met (Empagliflozin+Metformin) and Tiptengio (Empagliflozin+Linagliptin) in India. As per the International Diabetes Federation, India is home to 77 million adults aged between 20 and 79 years with diabetes,…